sorafenib eg 200 mg compr. pellic.
eg sa-nv - tosylate de sorafénib 274 mg - eq. sorafénib 200 mg - comprimé pelliculé - 200 mg - tosylate de sorafénib 274 mg - sorafenib
sorafenib eg 200 mg compr. pellic.
eg sa-nv - tosylate de sorafénib 274 mg - eq. sorafénib 200 mg - comprimé pelliculé - sorafenib
sorafenib accord
accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - agents antinéoplasiques - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.
apo-sorafenib comprimé
apotex inc - sorafénib (tosylate de sorafénib) - comprimé - 200mg - sorafénib (tosylate de sorafénib) 200mg
sorafenib eg 400 mg compr. pellic.
eg sa-nv - tosylate de sorafénib 548 mg - eq. sorafénib 400 mg - comprimé pelliculé - sorafenib